Experimental models of liver fibrosis

Autor(es):Mostrar menos -

Yanguas, Sara Crespo ^[1] ; Cogliati, Bruno ^[2] ; Willebrords, Joost ^[1] ; Maes, Michael ^[1] ; Colle, Isabelle ^[3] ; van den Bossche, Bert ^[4] ; Marques Souza de Oliveira, Claudia Pinto ^[5] ; Andraus, Wellington ^[6] ; Alves, Venancio Avancini ^[7] ; Leclercq, Isabelle ^[8] ; Vinken, Mathieu ^[1]

Afiliação do(s) autor(es)

^[1] Vrije Univ Brussel, Dept Vitro Toxicol & Dermatocosmetol, Fac Med & Pharm, Laarbeeklaan 103, B-1090 Brussels - Belgium

^[2] Univ Sao Paulo, Dept Pathol, Sch Vet Med & Anim Sci, Sao Paulo - Brazil

^[3] Algemeen Stedelijk Ziekenhuis, Dept Hepatogastroenterol, Aalst - Belgium

^[4] Algemeen Stedelijk Ziekenhuis, Dept Abdominal Surg & Hepatopancreaticobiliary Su, Aalst - Belgium

^[5] Univ Sao Paulo, Sch Med, Hepatol Branch, Dept Gastroenterol, Clin Div, Sao Paulo - Brazil

^[6] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo - Brazil

^[7] Univ Sao Paulo, Sch Med, Dept Pathol, Lab Med Invest, Sao Paulo - Brazil

^[8] Catholic Univ Louvain, Inst Rech Expt & Clin, Lab Hepatogastroenterol, B-1200 Brussels - Belgium

• Tipo de documento: Artigo de Revisão
• Fonte: ARCHIVES OF TOXICOLOGY; v. 90, n. 5, p. 1025-1048, MAY 2016.
• Citações Web of Science: 32

Resumo

Hepatic fibrosis is a wound healing response to insults and as such affects the entire world population. In industrialized countries, the main causes of liver fibrosis include alcohol abuse, chronic hepatitis virus infection and non-alcoholic steatohepatitis. A central event in liver fibrosis is the activation of hepatic stellate cells, which is triggered by a plethora of signaling pathways. Liver fibrosis can progress into more severe stages, known as cirrhosis, when liver acini are substituted by nodules, and further to hepatocellular carcinoma. Considerable efforts are currently devoted to liver fibrosis research, not only with the goal of further elucidating the molecular mechanisms that drive this disease, but equally in view of establishing effective diagnostic and therapeutic strategies. The present paper provides a state-of-the-art overview of in vivo and in vitro models used in the field of experimental liver fibrosis research. (AU)

• Processo FAPESP: 13/50420-6 - Canais de conexina e panexina como alvos terapêuticos e biomarcadores nas doenças hepáticas aguda e crônica
• Beneficiário: Mathieu Frederick Alexander Vinken
• Modalidade de apoio: Auxílio à Pesquisa - Programa SPEC